ClinicalTrials.gg
Not yet recruitingNCT06845241Updated Feb 25, 2025

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of ICP-490 in Relapsed or Refractory Non-Hodgkin Lymphoma, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Not yet recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.

Primary conditionLymphoma, Non-HodgkinRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
82nd of 183
68 · median 58
Started
2025
with 11 others
Phase 1/2
42 of 196
27 open now
Primary completion
2028-07
later than 87 of 109 live
Registered
173rd of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 82nd largest by planned enrollment of the 183 interventional ones that give a count, is one of 12 that started in 2025, is one of 42 in phase 1/2, reaches primary completion later than 87 of the 109 other live ones, and was the 173rd registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.

03

Conditions studied

  • Relapsed or Refractory Non-Hodgkin Lymphoma

Browse trials for

04

In context

Lymphoma, Non-Hodgkin Reclassified

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

This study's planned enrollment of 68 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years old.
  2. Diagnosed as non-hodgkin lymphoma .
  3. The patient must have measurable diseases.
  4. (ECOG) Performance Status (PS) score of 0-2.
  5. Patients must have adequate organ function.
  6. Expected survival time ≥ 3 months.
  7. All toxicities caused by prior anticancer therapy must have recovered to Grade ≤ 1 (based on v5.0) except alopecia and fatigue.
  8. Female patients of should have a negative blood pregnancy test result within 48 h prior to the first dose of drug.
  9. Male or Female of reproductive age must use from 28 days before the first dose until at least 6 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria

  1. Known active central nervous system (CNS) involvement Lymphoma.
  2. Excludes other active within 3 years before first dose, except locally curable cancers after radical treatment.
  3. Uncontrolled or severe cardiovascular disorders.
  4. Presence or history of CNS diseases.
  5. Any active infection requiring intravenous infusion for systemic treatment within 14 days prior to the first dose of the study drug.
  6. Presence or history existence of diseases restricted by the protocol.
  7. Major surgery within 28 days before first dose.
  8. Any serious or uncontrolled systemic disease that the investigator believes may increase the risk associated with participating in the study or the administration of the study drug, or may affect the patient's ability to receive the study drug.
  9. Patients who have received medications or foods with strong inhibitory or inductive effects on cytochrome P450 , and proton pump inhibitors within 2 weeks prior to the first dose of drug, or who are planning to receive proton pump inhibitors during the study.
  10. Patients with a history of intolerance to thalidomide, lenalidomide, or any component contained in the formulation of the investigational drug.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    ICP-490

    Drug: ICP-490

Interventions

  • DrugICP-490

    Specified dose on specified days

07

What researchers measure

Primary outcomes

  1. Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0

    Time frame: Through study completion,an average of 3 years

  2. Incidence, type, and severity of dose-limiting toxicities (DLTs);

    Time frame: Through study completion,an average of 3 years

  3. Recommended Phase 2 Doses(RP2Ds) and/or maximum tolerated doses(MTDs).

    Time frame: Through study completion,an average of 3 years

  4. ORR assessed according to the Lugano criteria (Cheson 2014).

    Time frame: Through study completion,an average of 3 years

Secondary outcomes

  1. PK parameters: maximum concentration (Cmax)

    Time frame: Through study completion,an average of 3 years

  2. PK parameters: time to maximum concentration (Tmax)

    Time frame: Through study completion,an average of 3 years

  3. PK parameters: half-life (T1/2)

    Time frame: Through study completion,an average of 3 years

  4. PK parameters: area under the concentration-time curve (AUC0-∞ and AUC0-t)

    Time frame: Through study completion,an average of 3 years

  5. PK parameters: apparent clearance (CL/F)

    Time frame: Through study completion,an average of 3 years

  6. PK parameters: apparent volume of distribution during terminal phase (Vz/F)

    Time frame: Through study completion,an average of 3 years

  7. PK parameters:Steady-state PK parameters

    Time frame: Through study completion,an average of 3 years

  8. The overall response rate (ORR) assessed according to the Lugano criteria (Cheson 2014).

    Time frame: Through study completion,an average of 3 years

  9. Complete response rate (CRR) assessed according to the Lugano criteria (Cheson 2014).

    Time frame: Through study completion,an average of 3 years

  10. Time to response (TTR) assessed according to the Lugano criteria (Cheson 2014).

    Time frame: Through study completion,an average of 3 years

  11. Duration of response (DOR) assessed according to the Lugano criteria (Cheson 2014).

    Time frame: Through study completion,an average of 3 years

  12. Progression-free survival (PFS) assessed according to the Lugano criteria (Cheson 2014).

    Time frame: Through study completion,an average of 3 years

  13. Overall survival (OS)

    Time frame: Through study completion,an average of 3 years

08

Study locations

6 sites
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Jul 2028, 41 months later.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's planned 41 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 25, 2025
StartEst.
Feb 2025
Primary completionEst.
Jul 2028
CompletionEst.
Dec 2028
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06845241
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Feb 2025 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 25, 2025

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion